Tilray Brands (TLRY)
(Delayed Data from NSDQ)
$2.10 USD
+0.08 (3.96%)
Updated May 3, 2024 04:00 PM ET
After-Market: $2.09 -0.01 (-0.48%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Tilray Brands, Inc. [TLRY]
Reports for Purchase
Showing records 41 - 60 ( 219 total )
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
1Q23 Preview, Tempered Estimates on Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: Fall Marks Busy News Flow Around Federal Legislation SAFE+
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
4Q22 Slightly Better, Synergies Drive Margins in ''23, Early Inflection?
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: State Legalization Drives Growth, Federal CAOA News Only
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Closes $155M Investment in HEXO, Lowering Estimates and PT $4 on Softness
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: Alternative Financing Solutions Remains In High Demand
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Weekly ReHash: Early Readthrough Into 1Q22 Confirms Industry Headwinds
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Industry 1Q22 Preview: Near-Term Softness on Consumer Headwinds, 2H22 Pick Up
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Takeaways from Analyst Day and Visibility on Path to $4B by FY24, Neutral
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
Company: Tilray Brands, Inc.
Industry: Medical - Drugs
3Q22 Soft, Ongoing Canadian Difficulty Offset By Int''l/U.S. CPG Progress
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S